Insulin-enhancing vanadium(III) complexes.
Simple, high-yield, large-scale syntheses of the V(III) complexes tris(maltolato)vanadium(III), V(ma)3, tris(ethylmaltolato)vanadium(III), V(ema)3, tris(kojato)vanadium(III) monohydrate, V(koj)3-H2O, and tris(1,2-dimethyl-3-hydroxy-4-pyridinonato)vanadium(III) dodecahydrate, V(dpp)3-12H2O, are described; the characterization of these complexes by various methods and, in the case of V(dpp)3-12H2O, by an X-ray crystal structure determination, is reported. The ability of these complexes to normalize glucose levels in the STZ-diabetic rat model has been examined and compared with that of the benchmark compound BMOV (bis(maltolato)oxovanadium(IV)), an established insulin-enhancing agent.
Melchior
M
M
Medicinal Inorganic Chemistry Group, Department of Chemistry and Faculty of Pharmaceutical Sciences, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.
Rettig
S J
SJ
Liboiron
B D
BD
Thompson
K H
KH
Yuen
V G
VG
McNeill
J H
JH
Orvig
C
C
D000818:Animals; D018360:Crystallography, X-Ray; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D007202:Indicators and Reagents; D007328:Insulin / Q000378:metabolism*; D008024:Ligands; D008297:Male; D008958:Models, Molecular; D009942:Organometallic Compounds / Q000737:chemistry / Q000627:therapeutic use; D010084:Oxidation-Reduction; D011728:Pyridones / Q000737:chemistry / Q000627:therapeutic use*; D011753:Pyrones / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013055:Spectrophotometry, Infrared; D013816:Thermodynamics; D014639:Vanadium
D007004:Hypoglycemic Agents; D007202:Indicators and Reagents; D007328:Insulin; D008024:Ligands; D009942:Organometallic Compounds; D011728:Pyridones; D011753:Pyrones; D014639:Vanadium